Post-transplant malignancy: Reducing the risk in kidney transplant recipients

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 11, 2011, Pages 1719-1729

  Wu, Christine ^a   Shapiro, Ron ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Immunosuppression; Kidney transplant; Mammalian target of rapamycin inhibitors; Post transplant malignancy

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; CYCLOPHOSPHAMIDE; EVEROLIMUS; IMIQUIMOD; INTERLEUKIN 10; OKT 3; PROSTATE SPECIFIC ANTIGEN; RAPAMYCIN; TACROLIMUS; TEMSIROLIMUS;

BLADDER CANCER; BREAST CANCER; BREAST EXAMINATION; CANCER RISK; CHRONIC LYMPHATIC LEUKEMIA; COLD ISCHEMIA; DISEASE ASSOCIATION; DNA DAMAGE; ENZYME LINKED IMMUNOSPOT ASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; GLOMERULONEPHRITIS; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS C; HUMAN; HYSTERECTOMY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; KIDNEY DONOR; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MULTIPLE MYELOMA; NONHUMAN; PAPANICOLAOU TEST; PATHOGENESIS; PHOTOTHERAPY; POLYMERASE CHAIN REACTION; PROSTATE CANCER; REVIEW; SARCOMA; SIGNAL TRANSDUCTION; SKIN CANCER; SURGICAL RISK; T CELL LEUKEMIA; UTERINE CERVIX CANCER;

AGING; ANIMALS; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; NEOPLASMS; RISK FACTORS;

EID: 79960241258     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.569708     Document Type: Review

References (107)

1. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999;12(23):1725-30
2. Meier-Kriesche HU, Ojo AO, Port FK, et al. Survival improvement among patients with end-stage renal disease: trends over time for transplant recipients and wait-listed patients. J Am Soc Nephrol 2001;12(6):1293-6 (Pubitemid 32472644)
3. Ojo AO, Port FK, Wolfe RA, et al. Comparative mortality risks of chronic dialysis and cadaveric transplantation in black end-stage renal disease patients. Am J Kidney Dis 1994;24(1):59-64 (Pubitemid 24212977)
4. Oniscu GC, Brown H, Forsythe JL. How great is the survival advantage of transplantation over dialysis in elderly patients? Nephrol Dial Transplant 2004;19(4):945-51 (Pubitemid 38455669)
5. Johnson DW, Herzig K, Purdie D, et al. A comparison of the effects of dialysis and renal transplantation on the survival of older uremic patients. Transplantation 2000;69(5):794-9 (Pubitemid 30174099)
6. Jones DG, Taylor AM, Enkiri SA, et al. Extent and severity of coronary disease and mortality in patients with end-stage renal failure evaluated for renal transplantation. Am J Transplant 2009;9(8):1846-52
7. Dantal J, Pohanka E. Malignancies in renal transplantation: an unmet medical need. Nephrol Dial Transplant 2007;22(Suppl 1):i4-10 (Pubitemid 47073738)
8. U S Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, Available from: www.usrds.org [Last accessed 22 November 2010]
9. Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1994 - 2003. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD; United Network for Organ Sharing, Richmond, VA; University Renal Research and Education Association, Ann Arbor, MI. Available from: http://optn.transplant. hrsa.gov/data [Last accessed 20 November 2010]
10. Australia and New Zealand Dialysis and Transplant Registry, 2009. Available from: http://www.anzdata.org.au/v1/annual-reports-download.html [Last accessed 22 November 2010]
11. van de Wetering J, Roodnat JI, Hemke AC, et al. Patient survival after the diagnosis of cancer in renal transplant recipients: a nested case-control study. Transplantation 2010;90(12):1542-6
12. Birkeland SA, Lokkegaard H, Storm HH. Cancer risk in patients on dialysis and after renal transplantation. Lancet 2000;355(9218):1886-7 (Pubitemid 30311885)
13. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004;4(6):905-13 (Pubitemid 38745589)
14. Webster AC, Craig JC, Simpson JM, et al. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients. Am J Transplant 2007;7(9):2140-51 (Pubitemid 47247055)
15. Rama I, Grinyo JM. Malignancy after renal transplantation: the role of immunosuppression. Nat Rev 2010;6(9):511-19
16. Buell JF, Beebe TM, Trofe J, et al. Donor transmitted malignancies. Ann Transplant 2004;9(1):53-6
17. Buell JF, Trofe J, Sethuraman G, et al. Donors with central nervous system malignancies: are they truly safe? Transplantation 2003;76(2):340-3 (Pubitemid 36927995)
18. Buell JF, Gross T, Alloway RR, et al. Central nervous system tumors in donors: misdiagnosis carries a high morbidity and mortality. Transplant Proc 2005;37(2):583-4 (Pubitemid 40590633)
19. Feng S, Buell JF, Chari RS, et al. Tumors and transplantation: the 2003 third annual ASTS State-of-the-Art Winter Symposium. Am J Transplant 2003;3(12):1481-7 (Pubitemid 37541505)
20. Lipshutz GS, Baxter-Lowe LA, Nguyen T, et al. Death from donor-transmitted malignancy despite emergency liver retransplantation. Liver Transpl 2003;9(10):1102-7 (Pubitemid 37304468)
21. National Cancer Institute SEER Cancer Statistics. Available from: http://www. cancer.org/Research/CancerFactsFigures/ index [Last accessed 22 November 2010]
22. Danpanich E, Kasiske BL. Risk factors for cancer in renal transplant recipients. Transplantation 1999;68(12):1859-64 (Pubitemid 30027338)
23. Torbenson MS, Wang J, Nichols L, et al. Occult nonhematopoietic malignancies present at autopsy in solid organ transplant patients who died within 100 days. Transplantation 2001;71(1):64-9 (Pubitemid 32105780)
24. Penn I. Evaluation of transplant candidates with pre-existing malignancies. Ann Transplant 1997;2(4):14-17
25. Yu H. Alcohol consumption and breast cancer risk. Jama 1998;280(13):1138-9
26. Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol 2002;3(9):565-74 (Pubitemid 34993644)
27. Rose RF, Moniem K, Seukeran DC, et al. Compliance of renal transplant recipients with advice about sun protection measures: completing the audit cycle. Transplant Proc 2005;37(10):4320-2 (Pubitemid 43016020)
28. Ducloux D, Courivaud C, Bamoulid J, et al. Pretransplant serum vitamin D levels and risk of cancer after renal transplantation. Transplantation 2008;85(12):1755-9
29. Kasiske BL, Cangro CB, Hariharan S, et al. The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant 2001;1(Suppl 2):3-95
30. Knoll G, Cockfield S, Blydt-Hansen T, et al. Canadian society of transplantation consensus guidelines on eligibility for kidney transplantation. CMAJ 2005;173(10):1181-4 (Pubitemid 41634920)
31. Smith RA, Cokkinides V, Brooks D, et al. Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2010;60(2):99-119
32. Doublet JD, Peraldi MN, Gattegno B, et al. Renal cell carcinoma of native kidneys: prospective study of 129 renal transplant patients. J Urol 1997;158(1):42-4 (Pubitemid 27251590)
33. Gulanikar AC, Daily PP, Kilambi NK, et al. Prospective pretransplant ultrasound screening in 206 patients for acquired renal cysts and renal cell carcinoma. Transplantation 1998;66(12):1669-72 (Pubitemid 29034989)
34. Chertow GM, Paltiel AD, Owen WF Jr, Lazarus JM. Cost-effectiveness of cancer screening in end-stage renal disease. Arch Intern Med 1996;156(12):1345-50 (Pubitemid 26196895)
35. Schwarz A, Vatandaslar S, Merkel S, Haller H. Renal cell carcinoma in transplant recipients with acquired cystic kidney disease. Clin J Am Soc Nephrol 2007;2(4):750-6
36. Ozcay F, Arslan H, Bilezikci B, et al. The role of valacyclovir on Epstein-Barr virus viral loads in pediatric liver transplantation patients. Transplant Proc 2009;41(7):2878-80
37. Funch DP, Walker AM, Schneider G, et al. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 2005;5(12):2894-900 (Pubitemid 43923949)
38. Humar A, Hebert D, Davies HD, et al. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder. Transplantation 2006;81(6):856-61
39. Opelz G, Daniel V, Naujokat C, Dohler B. Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma. Transplantation 2009;88(8):962-7
40. Eun JR, Lee HJ, Kim TN, Lee KS. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease. J Hepatol 2010;53(1):118-25
41. Lim LY, Kowdley KV. Chemoprevention of hepatocellular carcinoma in chronic hepatitis B with lamivudine? Gastroenterology 2005;129(6):2120-2; discussion 2
42. Saslow D, Castle PE, Cox JT, et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007;57(1):7-28 (Pubitemid 46148088)
43. Westman KW, Bygren PG, Olsson H, et al. Relapse rate, renal survival, and cancer morbidity in patients with Wegeners granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 1998;9(5):842-52 (Pubitemid 28209094)
44. Birkeland SA, Bendtzen K, Moller B, et al. Interleukin-10 and posttransplant lymphoproliferative disorder after kidney transplantation. Transplantation 1999;67(6):876-81 (Pubitemid 29169134)
45. Coomes SM, Wilke CA, Moore TA, Moore BB. Induction of TGF-beta 1, not regulatory T cells, impairs antiviral immunity in the lung following bone marrow transplant. J Immunol 2010;184(9):5130-40
46. Maluccio M, Sharma V, Lagman M, et al. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation 2003;76(3):597-602 (Pubitemid 37013269)
47. Harradine KA, Ridd K, Saunier EF, et al. Elevated cutaneous Smad activation associates with enhanced skin tumor susceptibility in organ transplant recipients. Clin Cancer Res 2009;15(16):5101-7
48. McAulay KA, Haque T, Crawford DH. Tumour necrosis factor gene polymorphism: a predictive factor for the development of post-transplant lymphoproliferative disease. Br J Cancer 2009;101(6):1019-27
49. Garnier JL, Blanc-Brunat N, Vivier G, et al. Interleukin-10 in Epstein-Barr virus-associated post-transplant lymphomas. Clin Transplant 1999;13(4):305-12 (Pubitemid 29392620)
50. Vajdic CM, McDonald SP, McCredie MR, et al. Cancer incidence before and after kidney transplantation. Jama 2006;296(23):2823-31 (Pubitemid 44969182)
51. Mihalov ML, Gattuso P, Abraham K, et al. Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center. Clin Transplant 1996;10(3):248-55 (Pubitemid 26257940)
52. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004;4(2):222-30 (Pubitemid 38248525)
53. Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998;351(9103):623-8 (Pubitemid 28098444)
54. Kehinde EO, Petermann A, Morgan JD, et al. Triple therapy and incidence of de novo cancer in renal transplant recipients. Br J Surg 1994;81(7):985-6 (Pubitemid 24230089)
55. Urwin HR, Jones PW, Harden PN, et al. Predicting risk of nonmelanoma skin cancer and premalignant skin lesions in renal transplant recipients. Transplantation 2009;87(11):1667-71
56. van Leeuwen MT, Webster AC, McCredie MR, et al. Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study. BMJ 2010;340:c570
57. Ben Mbarek L, Mebazaa A, Euvrard S, et al. 5% topical imiquimod tolerance in transplant recipients. Dermatology 2007;215(2):130-3 (Pubitemid 47230721)
58. Piaserico S, Belloni Fortina A, Rigotti P, et al. Topical photodynamic therapy of actinic keratosis in renal transplant recipients. Transplant Proc 2007;39(6):1847-50 (Pubitemid 47198804)
59. Ulrich C, Bichel J, Euvrard S, et al. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol 2007;157(Suppl 2):25-31 (Pubitemid 350179626)
60. Campistol JM, Albanell J, Arns W, et al. Use of proliferation signal inhibitors in the management of post-transplant malignancies-clinical guidance. Nephrol Dial Transplant 2007;22(Suppl 1):i36-41 (Pubitemid 47073743)
61. Campistol JM, Schena FP. Kaposis sarcoma in renal transplant recipients-the impact of proliferation signal inhibitors. Nephrol Dial Transplant 2007;22(Suppl 1):i17-22 (Pubitemid 47073740)
62. Gutierrez-Dalmau A, Campistol JM. The role of proliferation signal inhibitors in post-transplant malignancies. Nephrol Dial Transplant 2007;22(Suppl 1):i11-16 (Pubitemid 47073739)
63. Harwood CA, Attard NR, ODonovan P, et al. PTCH mutations in basal cell carcinomas from azathioprine-treated organ transplant recipients. Br J Cancer 2008;99(8):1276-84
64. ODonovan P, Perrett CM, Zhang X, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005;309(5742):1871-4 (Pubitemid 41325100)
65. Gutierrez-Dalmau A, Campistol JM. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs 2007;67(8):1167-98 (Pubitemid 46871026)
66. Kirk AD, Cherikh WS, Ring M, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 2007;7(11):2619-25 (Pubitemid 47561615)
67. Bustami RT, Ojo AO, Wolfe RA, et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004;4(1):87-93 (Pubitemid 38155493)
68. Snyder MJ, Stenzel TT, Buckley PJ, et al. Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation. Am J Surg Pathol 2004;28(6):794-800 (Pubitemid 38685894)
69. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8(2):128-35 (Pubitemid 34155123)
70. Luan FL, Ding R, Sharma VK, et al. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 2003;63(3):917-26 (Pubitemid 36315569)
71. Luan FL, Hojo M, Maluccio M, et al. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 2002;73(10):1565-72 (Pubitemid 34568667)
72. Stallone G, Infante B, Pontrelli P, et al. ID2-VEGF-related pathways in the pathogenesis of Kaposis sarcoma: a link disrupted by rapamycin. Am J Transplant 2009;9(3):558-66
73. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposis sarcoma in renal-transplant recipients. N Engl J Med 2005;352(13):1317-23 (Pubitemid 40411498)
74. Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005;80(7):883-9 (Pubitemid 41552882)
75. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009;87(2):233-42
76. Boratynska M, Banasik M, Patrzalek D, Klinger M. Impact of sirolimus treatment in kidney allograft recipients with prolonged cold ischemia times: 5-year outcomes. Exp Clin Transplant 2008;6(1):59-66 (Pubitemid 351983978)
77. Durrbach A, Rostaing L, Tricot L, et al. Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor. Transplantation 2008;85(3):486-90
78. Hsu HJ, Tian YC, Chen YC, et al. The combination of sirolimus and cyclosporine does not delay initial renal graft function recovery. Renal Fail 2008;30(3):303-6 (Pubitemid 351431220)
79. Barsoum RS, Morsey AA, Iskander IR, et al. The Cairo kidney center protocol for rapamycin-based sequential immunosuppression in kidney transplant recipients: 2-year outcomes. Exp Clin Transplant 2007;5(2):649-57 (Pubitemid 351146920)
80. Glotz D, Charpentier B, Abramovicz D, et al. Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids. Transplantation 2010;89(12):1511-17
81. Barth RN, Janus CA, Lillesand CA, et al. Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. Transpl Int 2006;19(11):885-92 (Pubitemid 44511112)
82. Cravedi P, Ruggenenti P, Remuzzi G. Sirolimus for calcineurin inhibitors in organ transplantation: contra. Kidney Int 2010;78:1068-74
83. Campistol JM, Cockwell P, Diekmann F, et al. Practical recommendations for the early use of m-TOR inhibitors (sirolimus) in renal transplantation. Transpl Int 2009;22(7):681-7
84. Furian L, Baldan N, Margani G, et al. Calcineurin inhibitor-free immunosuppression in dual kidney transplantation from elderly donors. Clin Transplant 2007;21(1):57-62 (Pubitemid 46189588)
85. House AA, Nguan CY, Luke PP. Sirolimus use in recipients of expanded criteria donor kidneys. Drugs 2008;68(Suppl 1):41-9 (Pubitemid 351601436)
86. Diekmann F, Campistol JM, Saval N, et al. Sequential quadruple immunosuppression including sirolimus in extended criteria and nonheartbeating donor kidney transplantation. Transplantation 2007;84(3):429-32 (Pubitemid 47258334)
87. Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant 2008;22(1):1-15 (Pubitemid 351149996)
88. Carmellini M, Collini A, Ruggieri G, et al. Excellent long-term results in de novo renal transplant recipients treated with proliferation signal inhibitors and reduced calcineurin inhibitors exposure. Transplant Proc 2008;40(6):1858-61
89. Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: a successful treatment for posttransplantation Kaposis sarcoma. Transplantation 2004;77(5):760-2 (Pubitemid 38366986)
90. Salgo R, Gossmann J, Schofer H, et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant 2010;10(6):1385-93
91. Dancey JE, Curiel R, Purvis J. Evaluating temsirolimus activity in multiple tumors: a review of clinical trials. Semin Oncol 2009;36(Suppl 3):S46-58
92. Hudes GR. Targeting mTOR in renal cell carcinoma. Cancer 2009;115(Suppl 10):2313-20
93. Kapoor A, Figlin RA. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma. Cancer 2009;115(16):3618-30
94. Chinnakotla S, Davis GL, Vasani S, et al. Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl 2009;15(12):1834-42
95. Saemann MD, Haidinger M, Hecking M, et al. The multifunctional role of mTOR in innate immunity: implications for transplant immunity. Am J Transplant 2009;9(12):2655-61
96. Augustine JJ, Chang PC, Knauss TC, et al. Improved renal function after conversion from tacrolimus/sirolimus to tacrolimus/mycophenolate mofetil in kidney transplant recipients. Transplantation 2006;81(7):1004-9 (Pubitemid 43670433)
97. Mendez R, Gonwa T, Yang HC, et al. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. Transplantation 2005;80(3):303-9 (Pubitemid 41129957)
98. Husain S, Raza K, Pilewski JM, et al. Experience with immune monitoring in lung transplant recipients: correlation of low immune function with infection. Transplantation 2009;87(12):1852-7
99. Anglicheau D, Suthanthiran M. Noninvasive prediction of organ graft rejection and outcome using gene expression patterns. Transplantation 2008;86(2):192-9
100. Heeger PS, Greenspan NS, Kuhlenschmidt S, et al. Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J Immunol 1999;163(4):2267-75 (Pubitemid 29382237)
101. Noris M, Casiraghi F, Todeschini M, et al. Regulatory T cells and T cell depletion: role of immunosuppressive drugs. J Am Soc Nephrol 2007;18(3):1007-18 (Pubitemid 46434518)
102. Hricik DE, Rodriguez V, Riley J, et al. Enzyme linked immunosorbent spot (ELISPOT) assay for interferon-gamma independently predicts renal function in kidney transplant recipients. Am J Transplant 2003;3(7):878-84 (Pubitemid 36827910)
103. Nickel P, Presber F, Bold G, et al. Enzyme-linked immunosorbent spot assay for donor-reactive interferon-gamma-producing cells identifies T-cell presensitization and correlates with graft function at 6 and 12 months in renal-transplant recipients. Transplantation 2004;78(11):1640-6 (Pubitemid 39648437)
104. Visonneau S, Cesano A, Torosian MH, et al. Growth characteristics and metastatic properties of human breast cancer xenografts in immunodeficient mice. Am J Pathol 1998;152(5):1299-311 (Pubitemid 28221882)
105. Stewart T, Tsai SC, Grayson H, et al. Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet 1995;346(8978):796-8
106. Kiberd BA, Rose C, Gill JS. Cancer mortality in kidney transplantation. Am J Transplant 2009;9(8):1868-75
107. Gill JS, Abichandani R, Kausz AT, Pereira BJ. Mortality after kidney transplant failure: the impact of non-immunologic factors. Kidney Int 2002;62(5):1875-83 (Pubitemid 35286299)